OUR FINDINGS PROVIDE US WITH A VITAL TOOL ENABLING SCREENING AND DEVELOPMENT OF FUTURE STRATEGIES
breakdown on muscle loss in CKD patients. Importantly, they compared these samples to cells from non-CKD patients; the first time this has been done. The team also exposed cells to different doses of a hormone called insulin-like growth factor 1 (IGF-1), which stimulates protein synthesis and the growth of muscle, to see if there was a difference in response between CKD and non-CKD cells.
The results of the research have certainly been promising and could help those involved in the treatment of CKD to develop new treatment options.
Promising results Results showed that cells from CKD patients had significantly higher levels of protein degradation, suggesting that the muscles of CKD patients experienced more breakdown than non-CKD patients. In addition, non-CKD patient cells exposed to IGF-1 showed an increase in protein synthesis, indicating muscle build up, but CKD patients showed very little response.
Through this innovative approach, the team have shown that CKD patients may lose muscle more quickly than non-CKD patients due to higher protein breakdown, and are also not able to rebuild muscle mass in the same way as patients without a CKD diagnosis.
‘Our findings,’ said Dr Baker, ‘provide us with a vital tool enabling screening and development of future strategies to treat the muscular weakness and dysfunction commonly reported by people living with CKD. We are currently using these results to inform the development of future medications, to improve the quality of life of those who live with CKD and suffer from these debilitating symptoms.’
‘Maintaining good quality of life remains a key challenge for patients living with kidney disease,’ added Dr Aisling McMahon, executive director of research and policy at Kidney Research UK, ‘and understanding the biological mechanisms than can contribute to these problems is crucial. Luke and his team have taken an important step forward in pinpointing the causes of muscle loss
and weakness that is so often reported by kidney patients, which will hopefully accelerate the assessment and development of new and effective solutions.’
The Scottish Medicines Consortium (SMC) has accepted the use of finerenone (Kerendia®) is accepted for use within NHSScotland.
‘Following a full submission,’ SMC said in its statement, ‘finerenone (Kerendia®) is accepted for use within NHSScotland for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
‘In a randomised, double-blind, phase III study, the addition of finerenone to angiotensin- converting enzyme inhibitor or angiotensin receptor blocker reduced the risk of the primary composite renal outcome comprising kidney failure, a sustained decrease in
estimated glomerular filtration rate of ≥40 per cent or death from renal causes compared with placebo.’
Dr Emma Watson
LUKE AND HIS TEAM HAVE TAKEN AN IMPORTANT STEP FORWARD IN PINPOINTING THE CAUSES OF MUSCLE LOSS AND WEAKNESS THAT IS SO OFTEN REPORTED BY KIDNEY PATIENTS
scottishpharmacist.com 31
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
